Falcon Wealth Planning Buys 158 Shares of Johnson & Johnson (NYSE:JNJ)

Falcon Wealth Planning lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,852 shares of the company’s stock after acquiring an additional 158 shares during the quarter. Falcon Wealth Planning’s holdings in Johnson & Johnson were worth $462,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Crestwood Advisors Group LLC grew its stake in shares of Johnson & Johnson by 1.0% during the 3rd quarter. Crestwood Advisors Group LLC now owns 391,942 shares of the company’s stock valued at $63,518,000 after acquiring an additional 3,701 shares during the period. Global Wealth Management Investment Advisory Inc. grew its stake in shares of Johnson & Johnson by 7.9% during the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 31,786 shares of the company’s stock valued at $5,151,000 after acquiring an additional 2,325 shares during the period. Heritage Investors Management Corp grew its stake in shares of Johnson & Johnson by 0.9% during the 3rd quarter. Heritage Investors Management Corp now owns 173,223 shares of the company’s stock valued at $28,073,000 after acquiring an additional 1,623 shares during the period. Hanlon Investment Management Inc. grew its stake in shares of Johnson & Johnson by 12.5% during the 3rd quarter. Hanlon Investment Management Inc. now owns 2,311 shares of the company’s stock valued at $375,000 after acquiring an additional 257 shares during the period. Finally, Pittenger & Anderson Inc. lifted its holdings in Johnson & Johnson by 1.3% in the 3rd quarter. Pittenger & Anderson Inc. now owns 83,383 shares of the company’s stock worth $13,513,000 after purchasing an additional 1,070 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. TD Cowen lowered their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Royal Bank of Canada boosted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $158.35 on Wednesday. The stock’s fifty day moving average is $163.09 and its 200 day moving average is $155.75. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm has a market capitalization of $381.25 billion, a PE ratio of 22.92, a PEG ratio of 2.84 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the firm posted $2.66 EPS. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.13%. Johnson & Johnson’s payout ratio is presently 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.